This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, Q. Articles by Chang, A. E. Search for Related Content PubMed PubMed Citation Articles by Li, Q. Articles by Chang, A. E.

Expanded Tumor-reactive CD4⁺ T-Cell Responses to Human Cancers Induced by Secondary Anti-CD3/Anti-CD28 Activation¹

Division of Surgical Oncology [Q. L., S. A. F., A. E. C.] and Department of Otolaryngology [C. R. B.], University of Michigan, Ann Arbor, Michigan 48109

Generation of tumor-reactive T cells in large numbers ex vivo is a requisite step in the adoptive immunotherapy of patients. We examined the immune responses of T cells derived from tumor vaccine-primed lymph nodes activated with anti-CD3 alone and with an anti-CD3/anti-CD28 combination. Nylon wool-purified CD3⁺ cells were isolated from vaccine-primed lymph nodes obtained from melanoma, renal cell, and head and neck cancer patients. In the absence of antigen-presenting cells, activation with anti-CD3/anti-CD28 greatly enhanced subsequent T-cell expansion in interleukin 2 (>100-fold), compared to anti-CD3 alone. CD4⁺ T cells were preferentially stimulated. In four of eight patients, we found evidence of CD4⁺ cellular responses to autologous tumors by cytokine release assays. Positively selected CD4⁺ cells activated with anti-CD3/anti-CD28 released greater amounts of cytokine (IFN- and granulocyte macrophage colony-stimulating factor) in response to autologous tumors compared to cells activated by anti-CD3 alone. The CD4⁺ reactivity was MHC class II restricted and appeared to be associated with the expression of class II molecules on the vaccinating tumor cells. The CD4⁺ T-cell responses to class II-restricted tumor-associated antigens in patients with renal cell cancers represent unique findings.

This article has been cited by other articles:

				T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses Cancer Res., June 1, 2008; 68(11): 4431 - 4441. [Abstract] [Full Text] [PDF]

				Q. Li, A. C. Grover, E. J. Donald, A. Carr, J. Yu, J. Whitfield, M. Nelson, N. Takeshita, and A. E. Chang Simultaneous Targeting of CD3 on T Cells and CD40 on B or Dendritic Cells Augments the Antitumor Reactivity of Tumor-Primed Lymph Node Cells J. Immunol., August 1, 2005; 175(3): 1424 - 1432. [Abstract] [Full Text] [PDF]

				Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]

				J. Skitzki, R. A. Craig, R. Okuyama, R. N. Knibbs, K. McDonagh, A. E. Chang, and L. M. Stoolman Donor Cell Cycling, Trafficking, and Accumulation during Adoptive Immunotherapy for Murine Lung Metastases Cancer Res., March 15, 2004; 64(6): 2183 - 2191. [Abstract] [Full Text] [PDF]

				A. E. Chang, Q. Li, G. Jiang, D. M. Sayre, T. M. Braun, and B. G. Redman Phase II Trial of Autologous Tumor Vaccination, Anti-CD3-Activated Vaccine-Primed Lymphocytes, and Interleukin-2 in Stage IV Renal Cell Cancer J. Clin. Oncol., March 1, 2003; 21(5): 884 - 890. [Abstract] [Full Text] [PDF]

				M. P. Rubinstein, A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, M. I. Nishimura, and D. J. Cole Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity J. Immunol., February 1, 2003; 170(3): 1209 - 1217. [Abstract] [Full Text] [PDF]

				A. Raiter, G. Rodionov, A. Novogrodsky, and B. Hardy CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation Int. Immunol., November 1, 2000; 12(11): 1623 - 1628. [Abstract] [Full Text] [PDF]

				M. Guttinger, F. Guidi, M. Chinol, E. Reali, F. Veglia, G. Viale, G. Paganelli, A. Corti, and A. G. Siccardi Adoptive Immunotherapy by Avidin-driven Cytotoxic T Lymphocyte- Tumor Bridging Cancer Res., August 1, 2000; 60(15): 4211 - 4215. [Abstract] [Full Text]